ACTEMRA (tocilizumab)
MONOCLONAL ANTIBODY, HUMAN INTERLEUKIN 6 INHIBITORS·GIANT CELL ARTERITIS·+4
GENENTECH
Indication
Cytokine release syndrome
Cytokine release syndrome is an acute systemic inflammatory response caused by the massive, rapid release of pro-inflammatory cytokines into the circulation. Read more about Cytokine release syndrome
7 drugs 6 manufacturers
Drugs that treat it
Common Cytokine release syndrome therapies.
TYENNE (tocilizumab-aazg)
MONOCLONAL ANTIBODY, HUMAN INTERLEUKIN 6 INHIBITORS·GIANT CELL ARTERITIS·+5
FRESENIUS KABI
TOFIDENCE (tocilizumab-bavi)
MONOCLONAL ANTIBODY, HUMAN INTERLEUKIN 6 INHIBITORS·GIANT CELL ARTERITIS·+5
BIOGEN-IDEC
TOFIDENCE (tocilizumab-bavi)
MONOCLONAL ANTIBODY, HUMAN INTERLEUKIN 6 INHIBITORS·GIANT CELL ARTERITIS·+5
BIOGEN/ORGANON
AVTOZMA (tocilizumab-anoh)
MONOCLONAL ANTIBODY, HUMAN INTERLEUKIN 6 INHIBITORS·GIANT CELL ARTERITIS·+5
CELLTRION USA,
AVTOZMA AUTOINJECTOR (tocilizumab-anoh)
MONOCLONAL ANTIBODY, HUMAN INTERLEUKIN 6 INHIBITORS·GIANT CELL ARTERITIS·+5
CELLTRION USA,
TOFIDENCE (tocilizumab-bavi)
MONOCLONAL ANTIBODY, HUMAN INTERLEUKIN 6 INHIBITORS·GIANT CELL ARTERITIS·+5
ORGANON LLC
Filter & compare in the drug finder →Opens the drug finder with Cytokine release syndrome preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonCytokine release syndrome is an acute systemic inflammatory response caused by the massive, rapid release of pro-inflammatory cytokines into the circulation.
It primarily occurs as a serious adverse complication in patients receiving targeted immunotherapies, most notably chimeric antigen receptor T-cell therapies and bispecific antibody constructs.
Pathophysiologically driven by the hyperactivation of T cells, monocytes, and macrophages, the syndrome is clinically characterized by persistent fever, tachycardia, fatigue, and headache, which can progress to profound hypotension, capillary leak, hypoxia, and multiorgan dysfunction.
- cancer.gov
Cytokine release syndrome is an acute systemic inflammatory response caused by the massive, rapid release of pro-inflammatory cytokines into the circulation Pathophysiologically driven by the hyperactivation of T cells, monocytes, and macrophages, the syndrome is clinically characterized by persistent fever, tachycardia, fatigue, and headache, which can progress to profound hypotension, capillary leak, hypoxia, and multiorgan dysfunction
- nih.gov
Cytokine release syndrome is an acute systemic inflammatory response caused by the massive, rapid release of pro-inflammatory cytokines into the circulation It primarily occurs as a serious adverse complication in patients receiving targeted immunotherapies, most notably chimeric antigen receptor T-cell therapies and bispecific antibody constructs Pathophysiologically driven by the hyperactivation of T cells, monocytes, and macrophages, the syndrome is clinically characterized by persistent feve...
- nih.gov
It primarily occurs as a serious adverse complication in patients receiving targeted immunotherapies, most notably chimeric antigen receptor T-cell therapies and bispecific antibody constructs
Personalize your experience
Follow Cytokine release syndrome and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.